HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Ballou, W. R. Articles by Cahill, C. P. Search for Related Content PubMed Articles by Ballou, W. R. Articles by Cahill, C. P.

Two Decades of Commitment to Malaria Vaccine Development: GlaxoSmithKline Biologicals

GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily on the company’s global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and commercialization. Through GSK’s pioneering business model and working in partnership with global vaccine funding agencies, the company is committed to seeing that, once approved, a safe and effective malaria vaccine will be available to everyone that needs it.

Received March 16, 2007. Accepted for publication March 28, 2007.

Acknowledgments: We are very grateful to the thousands of volunteers and their families who have taken part in trials of the GSK candidate malaria vaccines to date and acknowledge the efforts of the investigative teams in the United States, Europe, and Africa who have conducted the studies to date, the many GSK, WRAIR, and MVI staff who have worked hard to make the trials possible, the advisory board and Clinical Trials Partnership Committee that have guided the clinical development plan, and the data safety monitoring board and local safety monitors who have provided independent safety oversight for the trials.

Disclosure: W. Ripley Ballou and Conor Cahill are employees of GlaxoSmithKline Biologicals. W. Ripley Ballou holds shares in GlaxoSmithKline. Conor Cahill is a professional medical writer at GSK Biologicals. W. Ripley Ballou is listed as an "inventor" of patented malaria vaccines; however, he does not hold a patent for a malaria vaccine.

^* Address correspondence to W. Ripley Ballou, Global Clinical Research and Development, GlaxoSmithKline Biologicals, 89 Rue de l’Institut, Rixensart 1330, Belgium. E-mail: ripley.ballou{at}gskbio.com

Authors’ address: W. Ripley Ballou and Conor P. Cahill, Global Clinical Research & Development, GlaxoSmithKline Biologicals, 89 Rue de l’Institut, Rixensart 1330, Belgium.

This article has been cited by other articles:

				J. G. Breman, M. S. Alilio, and N. J. White Defining and Defeating the Intolerable Burden of Malaria III. Progress and Perspectives Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): vi - xi. [Full Text] [PDF]